ArticleFrontiers in cell and developmental biology2026
Study on the expression of lactate transport-related proteins in follicular lymphoma and their relationship with clinicopathologic features.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression of the lactate transport-related proteins MCT1, MCT4, and their chaperone CD147 in follicular lymphoma (FL), and to delineate their potential correlations with clinicopathological parameters predictive of prognosis. Methods: Immunohistochemistry was employed to evaluate the expression of MCT1, MCT4, and CD147 in tumor cells. Associations between protein expression and clinicopathological variables relevant to patient outcome were statistically analyzed. Results: 1. MCT1-positive immunoreactivity was significantly associated with elevated serum β2-microglobulin (β2-M, a small circulating protein that rises with disease activity and serves as a marker of tumor load and adverse outcomes in lymphomas) level, male sex, and Ki-67 ≥ 30%; MCT4-positive immunoreactivity was significantly associated with Ki-67 ≥ 30%; CD147-positive immunoreactivity correlated significantly with low-grade FL. 2. Four distinct expression patterns of MCT1/MCT4 were identified: double-positive, double-negative, MCT1-positive only, and MCT4-positive only. High-grade FL demonstrated a significant predilection for either double-positive or single-positive expression; Ki-67 < 30% was significantly linked to the double-negative expression; elevated serum β2-M was significantly associated with MCT1-positive only expression; age ≥60 years and female sex were significantly associated with MCT4-positive only expression. Conclusion: The expression of MCT1, MCT4, and CD147 in FL is correlated with adverse clinicopathological features, thereby furnishing additional evidence for refinement of the Follicular Lymphoma International Prognostic Index (FLIPI, a five-parameter clinical score predicting outcome in newly diagnosed follicular lymphoma). Targeted inhibition of MCT1 and MCT4 may represent a novel therapeutic strategy. Furthermore, the heterogeneous expression of these three proteins suggests metabolic heterogeneity within FL, offering a mechanistic basis for future investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.